Rockefeller Financial Services Inc. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 37.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 140,339 shares of the medical research company’s stock after selling 83,811 shares during the period. Rockefeller Financial Services Inc. owned about 0.07% of Edwards Lifesciences Corporation worth $15,340,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in EW. ETF Managers Group LLC purchased a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $112,000. Shine Investment Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $126,000. Cornerstone Advisors Inc. lifted its holdings in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares in the last quarter. Alexandria Capital LLC lifted its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $140,000. 81.90% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have issued reports on EW. Cowen and Company reaffirmed a “buy” rating and issued a $135.00 price target on shares of Edwards Lifesciences Corporation in a report on Thursday, October 12th. Barclays PLC reaffirmed an “equal weight” rating and issued a $120.00 price target on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Canaccord Genuity reaffirmed a “buy” rating and issued a $155.00 price target (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $115.00 price target on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 price target (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Edwards Lifesciences Corporation presently has an average rating of “Buy” and an average price target of $120.75.

In other Edwards Lifesciences Corporation news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, October 16th. The shares were sold at an average price of $108.54, for a total transaction of $2,057,918.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction on Friday, September 29th. The stock was sold at an average price of $108.86, for a total transaction of $576,958.00. The disclosure for this sale can be found here. Insiders have sold 201,161 shares of company stock worth $22,826,072 in the last ninety days. 2.13% of the stock is currently owned by insiders.

Edwards Lifesciences Corporation (EW) traded up 1.22% during midday trading on Monday, reaching $114.46. 762,963 shares of the company were exchanged. The firm has a market cap of $24.17 billion, a P/E ratio of 34.72 and a beta of 0.62. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The firm’s 50-day moving average is $111.15 and its 200-day moving average is $111.91.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same quarter in the previous year, the firm posted $0.76 earnings per share. Edwards Lifesciences Corporation’s revenue was up 10.9% compared to the same quarter last year. On average, equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

WARNING: “Edwards Lifesciences Corporation (EW) Shares Sold by Rockefeller Financial Services Inc.” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/23/edwards-lifesciences-corporation-ew-shares-sold-by-rockefeller-financial-services-inc.html.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.